NASDAQ:VACC Vaccitech - VACC Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Vaccitech plc Please log in to your account or sign up in order to add this asset to your watchlist. $2.23 -0.24 (-9.72%) (As of 03/28/2023 05:13 PM ET) Add Compare Share Share Today's Range$2.16▼$2.3150-Day Range$2.16▼$3.1552-Week Range$2.02▼$7.45Volume204,269 shsAverage Volume66,401 shsMarket Capitalization$83.18 millionP/E Ratio14.87Dividend YieldN/APrice Target$12.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Vaccitech MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside468.0% Upside$12.67 Price TargetShort InterestHealthy0.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 21 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($2.52) to ($3.05) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.47 out of 5 starsMedical Sector170th out of 1,002 stocksPharmaceutical Preparations Industry70th out of 488 stocks 3.5 Analyst's Opinion Consensus RatingVaccitech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.67, Vaccitech has a forecasted upside of 468.0% from its current price of $2.23.Amount of Analyst CoverageVaccitech has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.04% of the float of Vaccitech has been sold short.Short Interest Ratio / Days to CoverVaccitech has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Vaccitech has recently decreased by 16.57%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldVaccitech does not currently pay a dividend.Dividend GrowthVaccitech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VACC. Previous Next 3.0 News and Social Media Coverage News SentimentVaccitech has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Vaccitech this week, compared to 1 article on an average week.Search Interest20 people have searched for VACC on MarketBeat in the last 30 days. MarketBeat Follows4 people have added Vaccitech to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaccitech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.00% of the stock of Vaccitech is held by insiders.Percentage Held by InstitutionsOnly 27.07% of the stock of Vaccitech is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Vaccitech are expected to decrease in the coming year, from ($2.52) to ($3.05) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaccitech is 14.87, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 116.83.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaccitech is 14.87, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 93.00.Price to Book Value per Share RatioVaccitech has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Vaccitech (NASDAQ:VACC) StockVaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Read More Receive VACC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter. Email Address VACC Stock News HeadlinesMarch 28, 2023 | finanznachrichten.deVaccitech plc: Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis BMarch 28, 2023 | finance.yahoo.comVaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis BMarch 28, 2023 | Tradewins (Ad)Modern Day Options Trading For Beginners!These days it takes more than willpower to succeed on Wall Street and for new traders, even small mistakes can sink an account! With "Your Guide To Successful Options Trading" by expert Wendy Kirkland, you can avoid new trader pitfalls and learn to earn in this vicious market. March 28, 2023 | americanbankingnews.comBarclays Trims Vaccitech (NASDAQ:VACC) Target Price to $7.00March 27, 2023 | msn.comVaccitech Earnings Perspective: Return On Capital EmployedMarch 27, 2023 | benzinga.comUK leadership in health, food and sustainability prompts Milltrust to launch follow-on university venture fund.March 27, 2023 | msn.comNew $150m fund set to invest in ‘high-impact’ firms across food and healthcareMarch 25, 2023 | americanbankingnews.comVaccitech plc (NASDAQ:VACC) to Post FY2022 Earnings of $0.26 Per Share, HC Wainwright ForecastsMarch 28, 2023 | Weiss Ratings (Ad)Bank Accounts: Frozen!In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!March 24, 2023 | finanznachrichten.deVaccitech plc: Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate DevelopmentsMarch 24, 2023 | msn.comBanking Sector Worries Weigh on American Depositary Receipts of European EquitiesMarch 24, 2023 | benzinga.comVaccitech shares are trading higher after the company reported better-than-expected FY22 sales results.March 24, 2023 | finance.yahoo.comVaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate DevelopmentsMarch 22, 2023 | marketwatch.comInfluenza Vaccines Market Share and Forecast till 2031March 21, 2023 | americanbankingnews.comVaccitech (NASDAQ:VACC) Stock Rating Reaffirmed by HC WainwrightMarch 20, 2023 | finance.yahoo.comVaccitech’s VTP-200 Ph 1b/2 Study Demonstrates Favorable Tolerability and Immunogenicity Profile at Interim Analysis in Women with Low-Grade Human Papillomavirus (HPV)-related Cervical LesionsMarch 20, 2023 | finance.yahoo.comVaccitech Says Prime-boost Vaccine Study Data In Women With Low-grade HPV Lesions Is 'Promising Step In Right Direction'March 16, 2023 | finance.yahoo.comOwning 39% shares,institutional owners seem interested in Vaccitech plc (NASDAQ:VACC),March 13, 2023 | marketwatch.comProstate Cancer Vaccines Market to Grow Exponentially Due to Rising DemandMarch 6, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Esperion (ESPR) and Vaccitech Plc (VACC)February 2, 2023 | marketwatch.comProstate Cancer Vaccines Market : Research Report Analysis by Competitors, Sales, Revenue and Industry Size 2023 To 2028January 30, 2023 | msn.comVaccitech appoints new Chief Scientific OfficerJanuary 30, 2023 | finance.yahoo.comVaccitech Appoints Industry Veteran, Nadège Pelletier, Ph.D., as Chief Scientific OfficerJanuary 30, 2023 | ft.comThe growing tensions around spinouts at British universitiesJanuary 22, 2023 | sg.finance.yahoo.comVaccitech plc (VACC) stock historical prices & data – Yahoo FinanceJanuary 13, 2023 | finance.yahoo.comVaccitech (NASDAQ:VACC) adds US$10m to market cap in the past 7 days, though investors from a year ago are still down 73%January 10, 2023 | markets.businessinsider.comH.C. Wainwright Keeps Their Buy Rating on Renalytix AI (RNLX)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VACC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaccitech and its competitors with MarketBeat's FREE daily newsletter. Email Address VACC Company Calendar Last Earnings11/12/2021Today3/28/2023Next Earnings (Estimated)5/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VACC CUSIPN/A CIK1828185 Webwww.vaccitech.co.uk Phone44-0-18-6581-8808FaxN/AEmployees72Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.67 High Stock Price Forecast$16.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside+412.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.15 Trailing P/E Ratio16.47 Forward P/E RatioN/A P/E GrowthN/ANet Income$5.34 million Net Margins11.95% Pretax Margin27.77% Return on Equity2.13% Return on Assets1.89% Debt Debt-to-Equity RatioN/A Current Ratio15.58 Quick Ratio15.58 Sales & Book Value Annual Sales$44.70 million Price / Sales2.06 Cash FlowN/A Price / Cash FlowN/A Book Value$7.24 per share Price / Book0.34Miscellaneous Outstanding Shares37,300,000Free Float34,686,000Market Cap$92.13 million OptionableNot Optionable Beta0.21 Key ExecutivesMr. William J. Enright MBA (Age 59)CEO & Director Comp: $754.28kDr. Margaret Marshall M.D. (Age 65)Chief Medical Officer Comp: $547.97kMs. Sarah GilbertCo-FounderMr. Adrian Hill Ph.D.Co-Founder & Scientific AdvisorMs. Gemma BrownChief Financial OfficerMr. Chris Ellis (Age 62)Chief Operating Officer Dr. Thomas George Evans M.D. (Age 67)Chief Scientific Officer Mr. Graham Griffiths (Age 43)Chief Bus. Officer Ms. Elizabeth Eagling-Vose M.B.A.Head of Clinical OperationsBernie McDonaldHead of IPMore ExecutivesKey CompetitorsParatek PharmaceuticalsNASDAQ:PRTKXBiotechNASDAQ:XBITEton PharmaceuticalsNASDAQ:ETONBriaCell TherapeuticsNASDAQ:BCTXGossamer BioNASDAQ:GOSSView All CompetitorsInsiders & InstitutionsMillennium Management LLCBought 9,967 shares on 2/15/2023Ownership: 0.108%Baird Financial Group Inc.Bought 92,461 shares on 2/13/2023Ownership: 0.248%Graham GriffithsSold 10,000 sharesTotal: $73,900.00 ($7.39/share)Christopher EllisSold 450 sharesTotal: $2,151.00 ($4.78/share)Christopher EllisSold 2,175 sharesTotal: $10,527.00 ($4.84/share)View All Insider TransactionsView All Institutional Transactions VACC Stock - Frequently Asked Questions Should I buy or sell Vaccitech stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccitech in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VACC shares. View VACC analyst ratings or view top-rated stocks. What is Vaccitech's stock price forecast for 2023? 2 brokerages have issued twelve-month price targets for Vaccitech's shares. Their VACC share price forecasts range from $7.00 to $16.00. On average, they predict the company's share price to reach $12.67 in the next twelve months. This suggests a possible upside of 412.8% from the stock's current price. View analysts price targets for VACC or view top-rated stocks among Wall Street analysts. How have VACC shares performed in 2023? Vaccitech's stock was trading at $2.35 at the beginning of 2023. Since then, VACC stock has increased by 5.1% and is now trading at $2.47. View the best growth stocks for 2023 here. Are investors shorting Vaccitech? Vaccitech saw a decrease in short interest during the month of March. As of March 15th, there was short interest totaling 14,600 shares, a decrease of 16.6% from the February 28th total of 17,500 shares. Based on an average trading volume of 68,200 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the shares of the company are short sold. View Vaccitech's Short Interest. When is Vaccitech's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023. View our VACC earnings forecast. How were Vaccitech's earnings last quarter? Vaccitech plc (NASDAQ:VACC) announced its earnings results on Friday, November, 12th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.25. The firm had revenue of $0.02 million for the quarter, compared to analysts' expectations of $1.65 million. Vaccitech had a net margin of 11.95% and a trailing twelve-month return on equity of 2.13%. When did Vaccitech IPO? (VACC) raised $110 million in an initial public offering (IPO) on Friday, April 30th 2021. The company issued 6,500,000 shares at $16.00-$18.00 per share. Morgan Stanley, Jefferies, Barclays and William Blair acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager. What is Vaccitech's stock symbol? Vaccitech trades on the NASDAQ under the ticker symbol "VACC." Who are Vaccitech's major shareholders? Vaccitech's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Baird Financial Group Inc. (0.25%) and Millennium Management LLC (0.11%). Insiders that own company stock include Christopher Ellis, Graham Griffiths, Joseph Scheeren, Karen A Dawes, M&G Investment Management Ltd, Robin Wright and Sciences Innovation Plc Oxford. View institutional ownership trends. How do I buy shares of Vaccitech? Shares of VACC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Vaccitech's stock price today? One share of VACC stock can currently be purchased for approximately $2.47. How much money does Vaccitech make? Vaccitech (NASDAQ:VACC) has a market capitalization of $92.13 million and generates $44.70 million in revenue each year. The company earns $5.34 million in net income (profit) each year or $0.15 on an earnings per share basis. How can I contact Vaccitech? Vaccitech's mailing address is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. The official website for the company is www.vaccitech.co.uk. The company can be reached via phone at 44-0-18-6581-8808 or via email at ir@vaccitech.co.uk.. This page (NASDAQ:VACC) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.